Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹311 Cr
down ₹17.5 Cr vs Nov 2016
- Stocks held
- 27
- up 1 vs Nov 2016
- Top 10 weight
- 73.7%
- of the portfolio in its ten largest
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In December 2016 it disclosed 27 stocks worth ₹311 Cr, down ₹17.5 Cr from Nov 2016. Its largest positions were Sun Pharmaceutical Industries Limited (20.3%), Lupin Limited (10.8%), Dr. Reddy's Laboratories Limited (10.3%); the ten largest together made up 73.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 85.1% of its equity. Cash and debt stood at 1.4%. Compared with Nov 2016 the fund entered 1 new stock and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
95%
Top-10 weight is higher than 95% of peers
Breadth
11%
Holds more stocks than 11% of peers
Cash
20%
Holds more cash than 20% of peers
What these mean: concentration · cash
Holdings in December 2016
Download CSVEvery line the fund disclosed, with the change against Nov 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 20.35% | down 1.36 pts | ₹63.4 Cr | down ₹8 Cr | Trimmed |
| Lupin Limited | 10.84% | up 0.45 pts | ₹33.8 Cr | down ₹41 L | Trimmed |
| Dr. Reddy's Laboratories Limited | 10.29% | down 1.05 pts | ₹32 Cr | down ₹5.3 Cr | Trimmed |
| Cipla Limited | 9.90% | up 0.56 pts | ₹30.8 Cr | up ₹12 L | Held |
| Aurobindo Pharma Limited | 5.76% | down 0.28 pts | ₹17.9 Cr | down ₹1.9 Cr | Trimmed |
| Piramal Enterprises Limited | 3.87% | up 0.05 pts | ₹12 Cr | down ₹51 L | Trimmed |
| Alkem Laboratories Limited | 3.85% | up 0.04 pts | ₹12 Cr | down ₹52 L | Trimmed |
| Divi's Laboratories Limited | 3.26% | down 1.37 pts | ₹10.2 Cr | down ₹5.1 Cr | Trimmed |
| Laurus Labs Limited | 2.85% | up 2.85 pts | ₹8.9 Cr | up ₹8.9 Cr | New |
| Narayana Hrudayalaya Limited | 2.77% | up 0.13 pts | ₹8.6 Cr | down ₹6 L | Trimmed |
| Biocon Limited | 2.63% | up 0.23 pts | ₹8.2 Cr | up ₹28 L | Added |
| IPCA Laboratories Limited | 2.50% | down 0.08 pts | ₹7.8 Cr | down ₹70 L | Trimmed |
| Zydus Lifesciences Limited | 2.46% | down 0.16 pts | ₹7.7 Cr | down ₹97 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 2.38% | up 0.02 pts | ₹7.4 Cr | down ₹37 L | Trimmed |
| Syngene International Limited | 2.29% | up 0.03 pts | ₹7.1 Cr | down ₹30 L | Trimmed |
| Strides Pharma Science Limited | 1.89% | up 0.04 pts | ₹5.9 Cr | down ₹18 L | Trimmed |
| Pfizer Limited | 1.70% | up 0.08 pts | ₹5.3 Cr | down ₹3 L | Trimmed |
| Sanofi India Limited | 1.61% | up 0.03 pts | ₹5 Cr | down ₹19 L | Trimmed |
| Unichem Laboratories Limited | 1.44% | up 0.01 pts | ₹4.5 Cr | down ₹22 L | Trimmed |
| Cash, TREPS & receivables | 1.43% | down 0.40 pts | ₹4.5 Cr | down ₹1.6 Cr | Trimmed |
| Natco Pharma Limited | 1.13% | up 0.02 pts | ₹3.5 Cr | down ₹15 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 1.12% | up 0.07 pts | ₹3.5 Cr | up ₹2 L | Added |
| Indraprastha Medical Corporation Limited | 1.04% | up 0.03 pts | ₹3.2 Cr | down ₹7 L | Trimmed |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.84% | down 0.03 pts | ₹2.6 Cr | down ₹24 L | Trimmed |
| Shilpa Medicare Limited | 0.66% | up 0.05 pts | ₹2 Cr | up ₹4 L | Added |
| Torrent Pharmaceuticals Limited | 0.60% | up 0.01 pts | ₹1.9 Cr | down ₹9 L | Trimmed |
| Indoco Remedies Limited | 0.37% | up 0.02 pts | ₹1.2 Cr | up ₹1 L | Added |
| Thyrocare Technologies Limited | 0.16% | up 0.01 pts | ₹50 L | up ₹1 L | Added |
What changed, Nov 2016 to Dec 2016
New New positions (1)
- Laurus Labs Limited2.8% · ₹8.9 Cr
Exited Exited (0)
None.
Added Biggest additions
- Biocon Limitedup ₹28 L (+0.23% pts)
- Shilpa Medicare Limitedup ₹4 L (+0.05% pts)
- GlaxoSmithKline Pharmaceuticals Limitedup ₹2 L (+0.07% pts)
- Thyrocare Technologies Limitedup ₹1 L (+0.01% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Nov 2016, the weight rose most in Healthcare Services (+0.2 pts), and fell most in Pharmaceuticals & Biotechnology (−0.3 pts).
- Healthcare Services6.2% → 6.4%+0.2 pts
- Pharmaceuticals & Biotechnology85.4% → 85.1%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Dec 2015 | Jun 2016 | Sep 2016 | Nov 2016 | Dec 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 88.6% | 85.5% | 85.9% | 85.4% | 85.1% |
| Healthcare Services | 2.9% | 5.6% | 5.5% | 6.2% | 6.4% |
| Pharmaceuticals | 5.4% | 4.7% | 4.5% | 4.6% | 4.6% |
| Finance | 3.1% | 4.2% | 4.1% | 3.9% | 3.9% |
Allocation in Dec 2016change vs Nov 2016
- Pharmaceuticals & Biotechnology (18)85.1%▼ 0.3 pts
- Healthcare Services (4)6.4%▲ 0.2 pts
- Pharmaceuticals (4)4.6%
- Finance (1)3.9%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Dec 2016
1.4%
▼ 0.4 pts vs Nov 2016
- Cash alone
- 1.4%
- cash and net receivables
- A year earlier
- 10.8%
- Dec 2015 · now ▼ 9.3 pts
- Last 12 months
- 0.7% – 11.7%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.